These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 36594109)

  • 1. Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
    Dai J; Liu X; Li J; Qu T; Cui Y; Jin S; Zhang E; Guo R
    Thorac Cancer; 2023 Feb; 14(6):535-543. PubMed ID: 36594109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Zhang S; Li S; Liu J; Yang C; Zhang L; Bao H; Cheng Y
    Clin Lung Cancer; 2022 Mar; 23(2):159-169. PubMed ID: 34247986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) combined with chemotherapy or antiangiogenic therapy as first-line treatment in patients with EGFR-mutant non-small cell lung cancer: A systematic review and meta-analysis.
    Chen Y; Wen S; Wu Y; Shi L; Xu X; Shen B
    Crit Rev Oncol Hematol; 2021 Jul; 163():103393. PubMed ID: 34119658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Ma JT; Guo YJ; Song J; Sun L; Zhang SL; Huang LT; Jing W; Zhao JZ; Han CB
    Biomed Res Int; 2021; 2021():8850256. PubMed ID: 33575349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Antiangiogenic Agents Combined With EGFR Tyrosine Kinase Inhibitors in Treatment-naive Lung Cancer: A Meta-Analysis.
    Deng Z; Qin Y; Liu Y; Zhang Y; Lu Y
    Clin Lung Cancer; 2021 Jan; 22(1):e70-e83. PubMed ID: 33067126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced
    Chen F; Chen N; Yu Y; Cui J
    Front Oncol; 2020; 10():904. PubMed ID: 32714857
    [No Abstract]   [Full Text] [Related]  

  • 7. First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis.
    Mosca M; Conci N; Di Federico A; Tateo V; Favorito V; Zappi A; Gelsomino F; De Giglio A
    JCO Precis Oncol; 2023 May; 7():e2300073. PubMed ID: 37262392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
    Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
    Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 15. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
    Yan H; Li Q; Wang W; Zhen H; Cao B
    Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
    Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
    Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
    Zhao Y; He Y; Wang W; Cai Q; Ge F; Chen Z; Zheng J; Zhang Y; Deng H; Chen Y; Lao S; Liang H; Liang W; He J
    Lancet Oncol; 2024 Oct; 25(10):1347-1356. PubMed ID: 39159630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy of Synchronous Combination of Chemotherapy and EGFR TKIs for the First-Line Treatment of NSCLC: A Systematic Analysis.
    Yan H; Li H; Li Q; Zhao P; Wang W; Cao B
    PLoS One; 2015; 10(8):e0135829. PubMed ID: 26285137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
    Hu D; Zhou YY; Ma HB; Tao MM; Huang QZ; Yang ZZ; Zhou Q
    BMC Pulm Med; 2023 Jun; 23(1):207. PubMed ID: 37316870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis.
    Zhang L; Ren HW; Wu QL; Wu YJ; Song X
    Pathol Oncol Res; 2020 Apr; 26(2):1137-1143. PubMed ID: 31147837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.